Cancer Biomarkers Market was valued at US$ 9.96 Bn. in 2021. The Global Cancer Biomarkers Market size is estimated to grow at a CAGR of 47.25% over the forecast period.
Cancer Biomarkers Market Overview:In oncology, biomarkers are substances that a tumor or a particular human body reaction secretes to indicate the presence of malignancy. Using diverse genomes and proteomics methods, biomarkers enable early cancer detection and quick, noninvasive diagnosis of the disease. The report explores the Cancer Biomarkers market segments (Cancer Type, Biomarkers Type, Application, End-user, and Region). Data has been provided by market participants, and regions, (North America, Asia Pacific, Europe, Middle East & Africa, and South America). This market report provides a thorough analysis of the rapid advances that are currently taking place across all Technology sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2020. The report investigates the Cancer Biomarkers market drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Cancer Biomarkers market’s contemporary competitive scenario. To know about the Research Methodology :- Request Free Sample Report
Cancer Biomarkers Market Dynamics:Growing cancer awareness to drive market growth: Cancer biomarkers are widely utilized in personalized medicine, companion diagnostics, and other disease diagnostics, including risk assessment for disease and drug development. During the forecast period of 2022–2029, one of the key factors forecasted to propel the growth of the cancer biomarkers market is the increasing utilization of biomarkers in disease diagnosis. Rising levels of technical progress for the creation of cancer biomarkers: The difficulties in identifying and comprehending the roles and interactions of different proteins have been addressed by advances in array and proteomics technologies. These technical developments have greatly streamlined the process of discovering and creating novel cancer biomarkers. The existence of potential pipeline candidates increase market demand: The creation of novel biomarkers for the detection and management of cancer is a major focus of many pharmaceutical companies. Many potential candidates are nearing the end of their development cycles and are forecasted to offer the market a significant boost once they are introduced. Lack of reimbursement policies for testing limiting the market: The lack of reimbursement policies for biomarker testing in emerging and developed nations is one of the factors that is restricting the demand for these biomarkers globally, despite the rising prevalence of cancer around the world and the growing number of patients needing diagnostic tests. The high cost of cancer diagnosis and treatment in developing nations is another significant issue limiting the market's growth. Due to this, fewer patients are having biomarker testing, and more patients are favoring other inexpensive detection methods. Technical difficulties with collecting and storing samples: One of the main problems for service providers is sample collection, which is followed by sample access. These samples must be subjected to strict quality control, and they must be maintained properly to prevent loss. Additionally, several samples are needed for the procedures of risk identification, screening, diagnosis, and monitoring. Individualized medicine: For each patient, personalized medicine determines the best course of action. In some areas of personalized medicine, cancer biomarkers are particularly significant. The detection of these disorders is made possible by the consumables used in cancer biomarker testing. Products for cancer biomarker diagnostics are being employed as companion diagnostics for a number of experimental treatments. Difficulties with cancer biomarker validation: The process of validating cancer biomarkers involves assessing tests or gauging performance traits like sensitivity, specificity, and reproducibility. The establishment of cancer biomarkers as trustworthy instruments to support development, medical treatment, and investment decisions in biopharma is dependent on validation. Cancer Biomarkers Market Trends: Lung cancer is the second most common type of cancer and the main cause of cancer-related deaths for both men and women worldwide. Lung cancer is brought on by the unchecked growth of abnormal cells that multiply in one or both lungs. Although it can occur in nonsmokers, smokers are at a higher risk of developing lung cancer. The length of time and quantity of cigarettes smoked by the patient both enhance the risk of lung cancer. Occupational or environmental exposure to asbestos, certain metals, some organic compounds, radiation, air pollution, and diesel exhaust are other risk factors. The market's operating companies are forecast to drive the segment's growth through strategic initiatives. For instance, Amgen announced the introduction of Biomarker Assist in April 2021. This program aims to increase patient access to biomarker testing for those with metastatic (stage IV) non-small cell lung cancer (NSCLC). Patients who qualify for Biomarker Assist may be able to save money on biomarker testing. Also, because of the rising incidence of lung cancer worldwide, there would undoubtedly be an increase in the demand for diagnostic tools, which would fuel this market's growth in the years to come.
Cancer Biomarkers Market Segment Analysis:Based on Cancer Type, The market is divided into breast, prostate, colorectal, cervical, liver, and lung categories based on the kind. In 2021, breast cancer accounted for the largest sector. In 2021, breast, lung, and prostate cancer collectively accounted for more than 46% of total revenue. The two main elements influencing dominance are rising target population bases and rising knowledge of early testing. Lung cancer, on the other hand, is forecasted to experience the fastest growth during the forecast period. The category is expected to rise as more diagnostic tests are developed that focus on EGFR and BRAF mutations, which serve as vital biomarkers for the detection of non-small cell lung cancer. Based on Application, Cancer biomolecules are used in a number of industries, including medication research, diagnostics, and customized medicine. Because of factors such as the growing development of high specificity and sensitivity biomarker-based oncology tests, diagnostics was the market's primary revenue-generating application. Because of growing interest among healthcare professionals and rising demand, personalized medicine is expected to experience burgeoning growth. Additionally, rising acceptance of companion diagnostic tests for cancer medications are forecasted to support market growth.
Cancer Biomarkers Market Regional Insights:The North American region held the largest market share accounting for 42% in 2021. The North American region is expected to witness significant growth at a CAGR of 8.3% through the forecast period. A strong base of healthcare facilities, increasing investment from major players in the development of cutting-edge devices, an increase in the number of processes involved in drug development, the detection of specific tumors, the monitoring of the biological response to cancer therapy, and an increase in research activities have all contributed to North America's dominance of the cancer biomarkers market. Because of an increase in government initiatives to increase awareness, an increase in medical tourism, an increase in research activities in the region, a rise in cancer prevalence, and a growing demand for high-quality healthcare in the region, Asia-Pacific is expected to grow significantly between 2022 and 2029. In 2020, the highest 12-month cancer prevalence rate was found in North America. In North America, the 12-month prevalence rate for all cancers was 588 per 100,000 population. The objective of the report is to present a comprehensive analysis of the global Cancer Biomarkers Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Cancer Biomarkers Market dynamic, and structure by analyzing the market segments and projecting the Cancer Biomarkers Market size. Clear representation of competitive analysis of key players by Design, price, financial position, product portfolio, growth strategies, and regional presence in the Cancer Biomarkers Market make the report investor’s guide. Cancer Biomarkers Market Competitive Landscape: The main techniques used by these firms to achieve a solid market position include new product development, collaboration agreements with research institutes for the discovery of novel biomarkers, and mergers and acquisitions of small players. Abbott Laboratories, F.Hoffmann-LA Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., Affymetrix Inc., Illumina Inc., Agilent Technologies, Merck & Co. Inc.
Cancer Biomarkers Market Scope: Inquire before buying
Global Cancer Biomarkers Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 9.96 Bn. Forecast Period 2022 to 2029 CAGR: 18.2% Market Size in 2029: US $ 47.25 Bn. Segments Covered: by Cancer Type • Breast Cancer • Lung Cancer • Colorectal Cancer • Prostate Cancer • Others by Biomarker Type • Protein Biomarkers • Genetic Biomarkers • Other Cancer Biomarkers by Application • Drug discovery and Development • Diagnostics • Personalized medicine • Others by End-user • Pharmaceutical & Biotechnology Companies • Diagnostics & Research Laboratories • Hospitals & Specialty Clinics • Others
Cancer Biomarkers Market by Region• North America • Europe • Asia Pacific • Middle East and Africa • South America
Cancer Biomarkers Market Key Players:• Abbott Laboratories • F.Hoffmann-LA Roche Ltd. • QIAGEN • Thermo Fisher Scientific Inc. • Affymetrix Inc. • Illumina Inc. • Agilent Technologies • Merck & Co. Inc. • Hologic Inc. • Sino Biological Inc. • Becton, Dickinson and Company • PerkinElmer Inc. • Bristol-Myers Squibb • Bio-Rad Laboratories • Eli-Lilly and Company • Pfizer Inc. • GlaxoSmithKline Plc. • Novartis AG Frequently Asked Questions: 1] What segments are covered in the Global Cancer Biomarkers Market report? Ans. The segments covered in the Cancer Biomarkers Market report are based on Cancer Type, Biomarkers Type, Application, and End-user. 2] Which region is expected to hold the highest share in the Global Cancer Biomarkers Market? Ans. North America is expected to hold the highest share in the Cancer Biomarkers Market. 3] What is the market size of the Global Cancer Biomarkers Market by 2029? Ans. The market size of the Cancer Biomarkers Market by 2029 is expected to reach USD 47.25 Billion. 4] What is the forecast period for the Global Cancer Biomarkers Market? Ans. The forecast period for the Cancer Biomarkers Market is 2022-2029. 5] What was the market size of the Global Cancer Biomarkers Market in 2022? Ans. The market size of the Cancer Biomarkers Market in 2022 was valued at USD 14.66 Billion.
1. Global Cancer Biomarkers Market Size: Research Methodology 2. Global Cancer Biomarkers Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Cancer Biomarkers Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Cancer Biomarkers Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 4. Global Cancer Biomarkers Market Size Segmentation 4.1. Global Cancer Biomarkers Market Size, by Cancer Type (2022-2029) • Breast Cancer • Lung Cancer • Colorectal Cancer • Prostate Cancer • Others 4.2. Global Cancer Biomarkers Market Size, by Cancer Biomarkers Type (2022-2029) • Protein Biomarkers • Genetic Biomarkers • Other Cancer Biomarkers 4.3. Global Cancer Biomarkers Market Size, by Application (2022-2029) • Drug discovery and Development • Diagnostics • Personalized medicine • Others 4.4. Global Cancer Biomarkers Market Size, by End-user (2022-2029) • Pharmaceutical & Biotechnology Companies • Diagnostics & Research Laboratories • Hospitals & Specialty Clinics • Others 5. North America Cancer Biomarkers Market (2022-2029) 5.1. North America Cancer Biomarkers Market Size, by Cancer Type (2022-2029) • Breast Cancer • Lung Cancer • Colorectal Cancer • Prostate Cancer • Others 5.2. North America Cancer Biomarkers Market Size, by Biomarkers Type (2022-2029) • Protein Biomarkers • Genetic Biomarkers • Other Cancer Biomarkers 5.3. North America Cancer Biomarkers Market Size, by Application (2022-2029) • Drug discovery and Development • Diagnostics • Personalized medicine • Others 5.4. North America Cancer Biomarkers Market Size, by End-user (2022-2029) • Pharmaceutical & Biotechnology Companies • Diagnostics & Research Laboratories • Hospitals & Specialty Clinics • Others 5.5. North America Cancer Biomarkers Market, by Country (2022-2029) • United States • Canada • Mexico 6. European Cancer Biomarkers Market (2022-2029) 6.1. European Cancer Biomarkers Market, by Cancer Cancer Type (2022-2029) 6.2. European Cancer Biomarkers Market, by Biomarkers Type (2022-2029) 6.3. European Cancer Biomarkers Market, by Application (2022-2029) 6.4. European Cancer Biomarkers Market, by End-user (2022-2029) 6.5. European Cancer Biomarkers Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Cancer Biomarkers Market (2022-2029) 7.1. Asia Pacific Cancer Biomarkers Market, by Cancer Type (2022-2029) 7.2. Asia Pacific Cancer Biomarkers Market, by Biomarkers Type (2022-2029) 7.3. Asia Pacific Cancer Biomarkers Market, by Application (2022-2029) 7.4. Asia Pacific Cancer Biomarkers Market, by End-user (2022-2029) 7.5. Asia Pacific Cancer Biomarkers Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Cancer Biomarkers Market (2022-2029) 8.1. Middle East and Africa Cancer Biomarkers Market, by Cancer Type (2022-2029) 8.2. Middle East and Africa Cancer Biomarkers Market, by Biomarkers Type (2022-2029) 8.3. Middle East and Africa Cancer Biomarkers Market, by Application (2022-2029) 8.4. Middle East and Africa Cancer Biomarkers Market, by End-user (2022-2029) 8.5. Middle East and Africa Cancer Biomarkers Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Cancer Biomarkers Market (2022-2029) 9.1. South America Cancer Biomarkers Market, by Cancer Type (2022-2029) 9.2. South America Cancer Biomarkers Market, by Biomarkers Type (2022-2029) 9.3. South America Cancer Biomarkers Market, by Application (2022-2029) 9.4. South America Cancer Biomarkers Market, by End-user (2022-2029) 9.5. South America Cancer Biomarkers Market, by Country (2022-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Abbott Laboratories 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. F.Hoffmann-LA Roche Ltd. 10.3. QIAGEN 10.4. Thermo Fisher Scientific Inc. 10.5. Affymetrix Inc. 10.6. Illumina Inc. 10.7. Agilent Technologies 10.8. Merck & Co. Inc. 10.9. Hologic Inc. 10.10. Sino Biological Inc. 10.11. Becton, Dickinson and Company 10.12. PerkinElmer Inc. 10.13. Bristol-Myers Squibb 10.14. Bio-Rad Laboratories 10.15. Eli-Lilly and Company 10.16. Pfizer Inc. 10.17. GlaxoSmithKline Plc. 10.18. Novartis AG